International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-4
Original Research Article
PREVALENCE AND PATTERN OF DYSLIPIDEMIA IN NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS PATIENTS
Published
July 13, 2024
Abstract

Background: Type 2 Diabetes Mellitus (T2DM) is a prevalent metabolic disorder associated with significant cardiovascular risk, partly due to dyslipidemia. Dyslipidemia, characterized by abnormal lipid levels, is a common complication in T2DM patients and can contribute to the development of cardiovascular and cerebrovascular diseases. Aim & Objective: To determine the prevalence of dyslipidemia in newly diagnosed type 2 diabetes mellitus patients. Methodology: This cross-sectional study included 140 patients with newly diagnosed T2DM. Lipid profiles were measured, including total cholesterol, LDL-C, HDL-C, and triglycerides. Glycemic control was assessed via HbA1c levels. Demographic data such as age, gender, and Body Mass Index (BMI) categories were recorded. The prevalence of dyslipidemia and its association with these factors were analyzed using appropriate statistical tests. Results: The study found that 71.40% of patients had dyslipidemia. Elevated triglycerides were present in 57.10% of patients, low HDL-C in 50%, elevated LDL-C in 42.90%, and elevated total cholesterol in 35.70%. Dyslipidemia was more prevalent in males (78.6%) compared to females (64.3%) and increased with age and higher BMI. Poor glycemic control (HbA1c ≥ 7%) was significantly associated with a higher prevalence of dyslipidemia (80% vs. 50% with HbA1c < 7%, p=0.02). Conclusion: The study highlights a high prevalence of dyslipidemia among newly diagnosed T2DM patients, particularly in males, older individuals, those who are overweight or obese, and those with poor glycemic control. These findings underscore the need for integrated management strategies to address both glycemic and lipid abnormalities to improve cardiovascular health in T2DM patients. Routine monitoring of blood glucose and lipid profiles is essential for early detection and intervention

Recommended Articles
Loading Image...
Volume-5, Issue-4
Citations
1447 Views
104 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved